Intervention under investigation:
NMS: One consultation 7-14 days after presentation of prescription followed by another 14-21 days thereafter to identify problems with treatment and provide support if needed. Comparator: standard practice (no planned contact after initial prescription and counselling) Perspective: Health and social care provider (NHS &PSS) Time horizon: lifetime; Cost year: 2014; Costs and utilities discount rate: 3.5%. Model approach: (Figure 1 ) Treatment success was defined as patients reaching serum-uric-acid-levels <6mg/dL (sUAcontrolled). A Markov model was developed. Three health-states were included: sUAcontrolled; sUA-uncontrolled; death. sUA-uncontrolled is associated with more acute gout attacks, higher mortality and is more likely in non-adherent patients. Cycle length was 1 year. Within one year the mean sUA-level does not change significantly (± 0.1 mg/dL). After 2-4 weeks from treatment initiation the effect of ULT can be detected. Assuming a homogenous distribution within the patients an annual cycle length seemed appropriate. Starting age was 55. Data sources: Transition probability, utility and resource use data taken preferentially from uptodate UK sources that reflected characteristics of the population in the model.
Effect of NMS on ULT adherence:
To obtain the difference in adherence rate in standard practice and NMS arm the results of logistic regression (OR adjusted for pharmacy clustering, disease, age, sex and medication count) from the NMS RCT 1 were combined with the ULT (allopurinol) adherence rate from Kuo et al. 2 (See Table 1 ) Analysis: One-way sensitivity (OSA) and probabilistic sensitivity analyses (PSA) were performed to assess robustness of the results. The model was run at 10000 iterations, results were plotted on an ICER-scatter-plane and presented as a cost-effectiveness acceptability curve (CEAC). There was a 83% probability that NMS dominated SP and 98% probability that NMS was cost-effective at £20000 per QALY ceiling willingness-to-pay. 
Conclusion

Results
Why might NMS work in gout?
Gout is the most common type of inflammatory arthritis in United Kingdom (UK). EULAR and NICE recommend urate lowering therapy (ULT). Non-adherence with ULT is >60% in the UK. As lack of healthcare literacy especially concerning the role of ULT medication is the main reason for non-adherence, medicines-taking could be improved by an intervention such as NMS. There is currently no RCT of a gout-focused NMS service, but commissioners need evidence to support decisions around expanding NMS into other long term conditions. (-795.63, 646.50) 
